)
Visual
test
MorphoSys
MorphoSys (MOR) investor relations material
MorphoSys has been acquired by Novartis AG
MorphoSys Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary29 Aug, 2024
Executive summary
Novartis completed a public takeover of MorphoSys, acquiring over 91% of shares and initiating a delisting and merger squeeze-out of minority shareholders at €68.00 per share.
MorphoSys sold all rights to tafasitamab to Incyte for $25 million, classifying the tafasitamab business as discontinued operations.
Biogen acquired HI-Bio, in which MorphoSys held an 11.5% stake, for $1.15 billion upfront and up to $650 million in milestones; MorphoSys received $128 million for its share.
Significant management and supervisory board changes followed the Novartis takeover, including new CEO and CFO appointments.
Financial highlights
Group revenues from continued operations rose to €62.2 million in H1 2024 (H1 2023: €50.9 million), mainly from royalties.
Research and development expenses increased to €134.8 million (H1 2023: €105.0 million); combined selling, general, and administrative expenses surged to €233.3 million (H1 2023: €35.5 million), driven by share-based payment acceleration and Novartis transaction costs.
Net loss from continued operations was €390.2 million (H1 2023: €85.3 million loss); total net loss including discontinued operations was €394.2 million (H1 2023: €118.4 million loss).
Cash and financial assets totaled €512.3 million as of June 30, 2024 (Dec 31, 2023: €680.5 million).
No product sales revenue expected for 2024 following tafasitamab divestiture.
Outlook and guidance
2024 financial guidance for product sales revenue was revoked; no product sales expected this year.
R&D expenses for 2024 are expected to be €205–225 million, mainly for pelabresib and tulmimetostat development.
Selling, administrative, and general expenses are forecast at €260–270 million.
Liquidity is secured by a €500 million shareholder loan facility from Novartis, ensuring operations for at least 12 months.
Novartis takeover: impact on personnel costs?
Post-tafasitamab, what drives revenue growth?
Pelabresib MANIFEST-2: TSS statistical significance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
MorphoSys
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
MorphoSys AG is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. It offers MOR101 for the treatment of acute lymphoblastic leukemia. The company was founded in 1992 and is headquartered in Planegg, Germany.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage